Dr. Small is Professor of Medicine at UCSF. He holds a number of leadership roles, serving as Leader of the UCSF Prostate Cancer Program, and as Deputy Directorof the UCSF Helen Diller Family Comprehensive Cancer Center. He has served as Chief of the Division of Hematology and Oncology for 10 years, and most recently he has assumed the position of Chief Scientific Officerin the UCSF Helen Diller Family Comprehensive Cancer Center. Nationally, he serves on the ASCO Board of Directors, and chairs a number of External Advisory Boards for other Cancer Centers. Eric’s research interests lie in clinical and translational research in advanced prostate cancer, including trial design, and development of novel agents. He piloted the early trials targeting the androgen receptor in advanced prostate cancer, developing ketoconazole and contributing to an understanding of its mechanisms of activity and resistance. Subsequently Eric was centrally involved with the development of two novel androgen signaling inhibitors, abiraterone acetate and apalutamide, from first in human studies to FDA approval. Eric has also been involved in the early application of immunotherapy to prostate cancer, developing sipuleucel T from first in human studies through FDA approval, and undertaking the first in human testing of ipilimumab, the first immune check point inhibitor to be clinically developed.
David Dornan, is a senior vice president and head of research and manufacturing, joined Bolt Biotherapeutics in 2017. He is working to harness the exciting technologies at Bolt to discover and develop therapeutics that may exploit myeloid cell biology to generate a robust anti-tumor immune response. Prior to Bolt, David led Oncology Research at Gilead and was working to build a group dedicated to identifying and developing anti-cancer therapeutics that could have utility in PD-1/PD-L1-refractory patients that encompassed immuno-oncology and cancer driver targeted therapies. Before that, he spent 10 years at Genentech serving in roles of increasing responsibility and played key roles in target discovery and validation, as well as translational research programs to determine the optimum patient population that would benefit from Genentech’s anti-cancer therapeutics across large and small molecule programs.
Dr. Blackburn is presently the Chief Development Officer of Amygdala Neurosciences, a biopharmaceutical company developing ethical pharmaceuticals for the treatment of substance use disorders, including opioid, alcohol, nicotine, cocaine and methamphetamine use disorders. Dr. Blackburn was Senior Vice President, Drug Discovery & Development at CV Therapeutics, a biopharmaceutical company devoted to the discovery and development of drugs for cardiovascular diseases. In 1997, Dr. Blackburn joined CV Therapeutics to head its drug discovery unit, expanding his responsibilities in 2004 to include leading the clinical research and biometrics groups. While at CVT, the company successfully developed and commercialized two drugs and placed seven products into development for multiple cardiovascular and metabolic indications. Importantly, Dr Blackburn was a leading member of the team that discovered and developed regadenoson in the United States and Europe. Dr Blackburn devised the clinical development program and participated in every facet of the development of regadenoson. In 2009 Gilead Sciences acquired CV Therapeutics, upon which Dr Blackburn was founder, Chief Executive Officer, and President of Rapiscan Pharma Solutions (RPS), Inc which licensed rest of world rights for regadenoson from Gilead Sciences. Dr Blackburn led the team to commercialize Rapiscan(r) (regadenoson) within the European Union and several countries in the Middle East ultimately leading to the acquisition of RPS Inc by GE Healthcare in 2016. He has authored over 40 publications and is an inventor of more than 20 US patents. Dr. Blackburn earlier served as a Scientist at Genentech and received his BS in Chemistry from Texas Christian University and his PhD from the University of Texas at Austin, which was followed by post-doctoral appointments at Oxford University (UK) and Massachusetts Institute of Technology prior to joining Genentech, Inc.
Dr. Diamond is Professor, Pediatrics and Cellular and Molecular Pharmacology, Founding Director, Ernest Gallo Clinic and Research Center, a member of the Executive Committee at the Center for the Neurobiology of Addiction and Vice-Chairman, Department of Neurology at the University of California, San Francisco. Ivan has worked over several decades as a pioneer on GPCR research in drug addiction, focusing on adenosine, dopamine, opioid receptor and other GPCRs. He also promoted the translational research of adenosine A2a receptor antagonist for drug addition, CNS disorders and cancer treatment. Ivan is Co-founder, Chief Scientific Officer and member of the Board of Directors at Amygdala Neurosciences. His work on selective and reversible aldehyde dehydrogenase 2 (ALDH2) inhibitor is in Phase 2 clinical development and planned to advance to Phase 3 clinical studies. Ivan was Senior Advisor at Gilead Sciences and the Vice President of Neuroscience at CV Therapeutics. He received M.D. and Ph.D. from University of Chicago and completed a residency in Neurology at the University of Chicago School of Medicine, followed by postdoctoral fellowship at Harvard Medical School.